Please assess the completion status of the following clinical trial:

Trial Title: A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have single or recurrent unipolar major depressive disorder (MDD) without psychotic features by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision (DSM-IV-TR) clinical assessment~* Have a total score ≥22 on the 17-item Hamilton Depression Rating Scale (HAM-D17) at screening and randomization~* Have treatment-resistant depression (TRD), defined as having failed to achieve a satisfactory antidepressant response, in the opinion of the investigator, to separate treatment courses of at least 2 different antidepressants, other than fluoxetine, of adequate dosage and duration (≥6 weeks) within the current major depressive episode~Exclusion Criteria:~* Have a diagnosis of Parkinson's disease or a related disorder~* Have a current or lifetime diagnosis of any of the following conditions, according to DSM-IV-TR criteria: Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder; Delusional Disorder; Psychotic Disorder Not Otherwise Specified; Bipolar Disorder I or II; Delirium of any type; Dementia of any type; Amnestic Disorder; any Substance-Induced Disorder; or any Psychotic Disorder due to a General Medical Condition~* Have a current diagnosis of post-partum depression or MDD with a seasonal pattern as defined in the DSM-IV-TR~* Have paranoid, schizoid, schizotypal, antisocial, or borderline personality disorder (Axis II) as a comorbid or primary diagnosis, based on DSM-IV-TR criteria~* Have DSM-IV-TR substance dependence/abuse or are not willing to avoid use of the substance (not including dependence on nicotine or caffeine) within 30 days of screening~* Are actively suicidal in the judgment of the investigator~* Have uncorrected narrow-angle glaucoma~* Have had one or more seizures without a clear and resolved etiology~* Have leukopenia~* Have any acute, serious, or unstable medical conditions~* Have an increased serum prolactin concentration at screening~* Have a rate-corrected cardiac QT interval, calculated using Bazett's formula (QTc Bazett's \[Rate-corrected cardiac QT interval on electrocardiogram calculated using Bazett's formula(QTcB)\]), on Electrocardiogram (ECG) \>450 milliseconds (male) or \>470 milliseconds (female) at screening~* Have a history of allergic reaction to olanzapine, fluoxetine, or olanzapine in combination with fluoxetine~* Have had treatment with olanzapine, fluoxetine, or olanzapine in combination with fluoxetine withdrawn due to clinically significant and/or intolerable adverse effects within 6 months of screening~* Have received treatment with remoxipride within 6 months of randomization~* Have received treatment with depot antipsychotics within one dosing interval before randomization~* Have received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS) treatment within the current MDD episode, or has a history of failure to respond to adequate treatment courses of ECT or VNS, or is expected to require ECT or VNS at any time during the study~* Have received previous treatment with clozapine~* Have received treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of screening, or are expected to need MAOI treatment at any time during the study or up until 5 weeks after study discontinuation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Olanzapine + Fluoxetine (Type: EXPERIMENTAL): Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks.~Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks.
- Placebo + Fluoxetine (Type: PLACEBO_COMPARATOR): Placebo matches the Olanzapine tablet for blinding.~Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy